Patents for A61P 35 - Antineoplastic agents (221,099)
09/2000
09/08/2000WO2000052046A1 Immunomodulating glycopeptide
09/08/2000WO2000052045A2 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
09/08/2000WO2000052038A1 Oligomers substituted by phosphonic acid ester, phosphonic acid or carbaborane functions and the corresponding pna monomers
09/08/2000WO2000052033A1 Novel cyclic tetrapeptide derivatives and use thereof as drugs
09/08/2000WO2000052031A2 Kit for radiolabeling proteins with yttrium-90
09/08/2000WO2000052028A1 TUMOR NECROSIS FACTOR RECEPTORS 6α and 6$g(b)
09/08/2000WO2000052021A1 Novel sulfofucosylacylglycerol derivatives and utilization thereof as drugs
09/08/2000WO2000052020A1 Novel sulforhamnosylacylglycerol derivatives and utilization thereof as drugs
09/08/2000WO2000051991A1 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
09/08/2000WO2000051968A1 Method for the preparation of a chiral-beta-amino ester
09/08/2000WO2000051959A1 Fluorinated chalcone derivatives or salts thereof and drugs containing the same as the active ingredient
09/08/2000WO2000051686A1 Use of integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia
09/08/2000WO2000051685A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
09/08/2000WO2000051645A1 Polymer compositions for polynucleotide delivery
09/08/2000WO2000051622A1 Drugs containing sulfopyranosylacylglycerol derivatives
09/08/2000WO2000051614A1 Inhibitors of prenyl-protein transferases
09/08/2000WO2000051613A1 Upper hitch link
09/08/2000WO2000051612A1 Inhibitors of prenyl-protein transferase
09/08/2000WO2000051611A1 Inhibitors of prenyl-protein transferase
09/08/2000WO2000051595A1 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using r(-)-ketoprofen
09/08/2000WO2000051547A2 Inhibitors of prenyl-protein transferase
09/08/2000WO2000035407A3 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
09/08/2000WO2000029583A3 Immunoglobulin superfamily proteins
09/08/2000WO2000027414A3 Inhibition of the formation of vascular hyperpermeability
09/08/2000WO2000024361A3 Bis(haloethyl)aminobenzene derivatives
09/08/2000WO2000023592B1 Minimal promoters and uses thereof
09/08/2000WO2000023573A3 Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
09/08/2000WO2000020026A3 Compositions and methods for inhibiting angiogenesis
09/08/2000WO2000019206A9 Ykl-40 as a marker and prognostic indicator for cancers
09/08/2000WO2000018212A9 Platelet-derived growth factor c, dna coding therefor, and uses thereof
09/08/2000WO2000012720A3 Elongase genes and uses thereof
09/08/2000WO2000012702A3 Human genes differentially expressed in colorectal cancer
09/08/2000WO2000004921A9 Avian leukosis virus subgroup j envelope gene product for diagnosis and vaccine
09/08/2000WO1999061068A9 Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
09/08/2000WO1999034784A3 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
09/08/2000CA2368539A1 Tumor-associated antigen
09/08/2000CA2364492A1 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
09/08/2000CA2364127A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
09/08/2000CA2364006A1 Polymer compositions for polynucleotide delivery
09/08/2000CA2364002A1 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
09/08/2000CA2363957A1 Immunomodulating glycopeptide
09/08/2000CA2363169A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2363139A1 Methods and reagents for inhibiting angiogenesis
09/08/2000CA2363077A1 Methods for targeting rna molecules
09/08/2000CA2362995A1 Anti-neoplastic compositions and uses thereof
09/08/2000CA2362825A1 Cdna for human methylenetetrahydrofolate reductase
09/08/2000CA2362817A1 Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof
09/08/2000CA2362778A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2362495A1 Inhibitors of prenyl-protein transferases
09/08/2000CA2362494A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2362493A1 Inhibitors of prenyl-protein transferase
09/08/2000CA2362489A1 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using r(-)-ketoprofen
09/07/2000DE19910403A1 Medicaments containing hydroxy-benzo-cyclopentabenzazepine-dione derivatives, useful as cellular hyperproliferation inhibitors, especially antitumor agents
09/07/2000DE19909503A1 Tumorassoziiertes Antigen Tumor-associated antigen
09/06/2000EP1033372A1 Compounds with antitumor activity
09/06/2000EP1033369A1 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY
09/06/2000EP1032838A1 125 human secreted proteins
09/06/2000EP1032706A1 Reagents and methods useful for detecting diseases of the breast
09/06/2000EP1032696A1 Vector for tissue-specific replication and gene expression
09/06/2000EP1032682A1 Desaturase genes and their use
09/06/2000EP1032672A1 Dna19355 polypeptide, a tumor necrosis factor homolog
09/06/2000EP1032671A1 Mammalian cytokine-like polypeptide-10
09/06/2000EP1032670A1 Toso
09/06/2000EP1032667A2 A33-related antigens and their pharmacological uses
09/06/2000EP1032656A1 Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor
09/06/2000EP1032596A1 Lactalbumin production process
09/06/2000EP1032582A1 NOVEL recJ
09/06/2000EP1032575A1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
09/06/2000EP1032426A1 Therapeutic agents
09/06/2000EP1032420A1 Immunoglobulin molecules having a synthetic variable region and modified specificity
09/06/2000EP1032417A1 Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens
09/06/2000EP1032412A1 Use of heparin-binding protein for the modulation or prophylaxis of apoptosis of mammalian cells
09/06/2000EP1032408A1 Galenic preparation for prevention and treatment of hepatocarcinoma
09/06/2000EP1032405A1 Antimutagenic compositions for treatment and prevention of photodamage to skin
09/06/2000EP1032393A1 QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
09/06/2000EP1032369A1 Targeted liposome gene delivery
09/06/2000EP1032304A1 Reagent for tumor therapy and/or imaging
09/06/2000EP1032271A1 Purging of stem cell products
09/06/2000EP1032269A1 Treatment of neoplasms with viruses
09/06/2000EP0912172B1 Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment
09/06/2000EP0901379B1 Type-2 chemokine binding proteins and methods of use therefor
09/06/2000EP0770089B1 Growth differentiation factor-12
09/06/2000EP0642345B1 Halichondrins and related compounds
09/06/2000CN1265741A Method and compositions for overcoming resistance to biologic and chemotherapy
09/06/2000CN1265674A 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
09/06/2000CN1265673A Dipeptide compounds which inhibit leukocyte adhesion medicated by VLA-4
09/06/2000CN1265669A Compounds which inhibit leukocyte adhesion mediated by VLA-4
09/06/2000CN1265668A Subtsituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
09/06/2000CN1265657A Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
09/06/2000CN1265647A Acrylic metalloprotease inhibitor
09/06/2000CN1265646A Aryloxyarylsulfonylamino hydroxamic acid derivatives
09/06/2000CN1265645A Urokinase inhibitors
09/06/2000CN1265600A Cloning pigs using donor nuclei from differentiated cells
09/06/2000CN1265590A Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels
09/06/2000CN1056153C Peptide inhibitors of mitogenesis and motorgenesis
09/06/2000CN1056141C 哌嗪衍生物 Piperazine derivatives
09/06/2000CN1056084C Immunotoxins directed against CD33 related surface antigens
09/06/2000CN1056082C Anticancer drug
09/06/2000CN1056064C Medicine for curing liver cancer and its making method
09/05/2000US6114568 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors